A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled safety and efficacy study of SPD503 [Intinuv; guanfacine] in children and adolescents aged 6-17 with attention deficit hyperactivity disorder (ADHD).

Trial Profile

A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled safety and efficacy study of SPD503 [Intinuv; guanfacine] in children and adolescents aged 6-17 with attention deficit hyperactivity disorder (ADHD).

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Guanfacine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2009 Atual number of patients (324) added as reported by ClinicalTrials.gov.
    • 01 Feb 2009 Primary endpoint 'change from baseline to endpoint in Attention Deficit Hyperactivity Disorder Rating Scale' has been met.
    • 01 Feb 2009 Results reported in the Journal of the American Academy of Child and Adolescent Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top